<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200616047788N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-07-21</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>Comparing two respiratory support methods in RDS treatment of premature neonates</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Continuous Positive Airway Pressure (CPAP) and Heated Humidified High Flow Nasal Cannula (HFNC) methods in treatment of neonates with respiratory distress syndrome with gestational age 28-34 weeks</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-06-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/49079</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Cases will be divided into 2 groups based on random block permutations. random sequences will be obtained from www.sealedenvelope.com, section: create a randomization list then the patients admitted to the NICU will be divided to A &amp; B groups as:
A,A,A,B,A,B,B,A,B,A,A,B,B.</study_design>
      <phase>N/A</phase>
      <hc_freetext>neonatal respiratory distress syndrome.</hc_freetext>
      <i_freetext>Intervention 1: In the CPAP group we will use Fabian CPAP PLUS ( Acutronic medical system, Switzerland) and Fisher &amp; Paykel humidifiers (Auckland, News land). patients will receive positive end-expiratory pressure all day long until we can reduce fio2 to 30% and peep to 3 cmH2o. Intervention 2: In the HFNC group we will use Sindi 1080 (medinSINDI® medical innovations, Germany )  and Fisher &amp; Paykel humidifiers (Auckland, News land) .  patients will receive positive end-expiratory pressure all day long until we can reduce fio2 to 30% and flow to 3 lit/min.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is no more information is available</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammd Reza Aramesh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini hospital</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6193673166</zip>
        <telephone>+98 61 3222 6104</telephone>
        <email>Aramesh-m@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Reza Aramesh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini hospital</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6193673166</zip>
        <telephone>0986132216502</telephone>
        <email>arameshmr@gmail.com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All preterm newborns with gestational age 28 -34 weeks, admitted to Imam Khomeini hospital, Ahvaz, 2020-2021</inclusion_criteria>
      <agemin>1 day</agemin>
      <agemax>7 days</agemax>
      <gender>Both</gender>
      <exclusion_criteria>major congenital anomaly, 
cyanotic congenital heart disease, 
neuromuscular disease, 
sepsis, 
congenital pneumonia, 
inborn errors of metabolism, 
meconium aspiration syndrome, 
perinatal asphyxia, 
APGAR score=&lt; 5 at 5 minutes, 
intubation at birth or prolonged positive ventilation at the delivery room, 
severe RDS necessitating intubation at birth based on NRP guidelines, 
severe cardiovascular instability, 
absence of spontaneous respiration and recurrent apnea, 
no respiratory distress.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the CPAP group we will use Fabian CPAP PLUS ( Acutronic medical system, Switzerland) and Fisher &amp; Paykel humidifiers (Auckland, News land). patients will receive positive end-expiratory pressure all day long until we can reduce fio2 to 30% and peep to 3 cmH2o.</i_keyword>
      <i_keyword>In the HFNC group we will use Sindi 1080 (medinSINDI® medical innovations, Germany )  and Fisher &amp; Paykel humidifiers (Auckland, News land) .  patients will receive positive end-expiratory pressure all day long until we can reduce fio2 to 30% and flow to 3 lit/min.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>All premature infants with RDS sore &lt;8. Timepoint: Rds score prior and after intervention. Method of measurement: Modified Downe's scoring system.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Need to intubation during first 72 hours of birth. Timepoint: third day of life. Method of measurement: physical examination, ABG, pulse oxymetry.</sec_outcome>
      <sec_outcome>Intraventricular hemorrhage. Timepoint: from birth to discharge if complications associated with IVH appear (  Anemia, a decrease of consciousness, change of vital signs). Method of measurement: brain sonography.</sec_outcome>
      <sec_outcome>Chronic lung disease. Timepoint: day 28 of life. Method of measurement: need to Fio2&gt; 21%.</sec_outcome>
      <sec_outcome>Patent ductus arteriosus requiring medical treatment. Timepoint: from 3rd to 7th day of life if symptoms associated with PDA appear( need to a higher fio2 , bounding pulses). Method of measurement: echocardiography.</sec_outcome>
      <sec_outcome>Air leak syndromes. Timepoint: from birth until receiving CPAP or HFNC. Method of measurement: physical examination, CXR.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-06-07</approval_date>
        <contact_name>Ethics committee of  Ahvaz Jundishapur university of medical sciences</contact_name>
        <contact_address>Golestan Blvd, Ahvaz, Iran Ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
